Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism

Prostate

Volumn 74, Issue 3, 2014, Pages 273-285

  Doherty, Declan ^a   Dvorkin, Scarlett Anne ^a   Rodriguez, Edna Patricia ^a   Thompson, Paul Daniel ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

AKR1C; CYP3A; metabolism; prostate cancer; vitamin D receptor

Indexed keywords

16 ALPHA HYDROXY PRASTERONE; 6BETA HYDROXYTESTOSTERONE; ANDROGEN; CALCITRIOL; CHOLESTEROL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; LIGAND; LUCIFERASE; MESSENGER RNA; PRASTERONE; SEOCALCITOL; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROID METABOLISM; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84892431708     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22748     Document Type: Article

References (54)

1. Skowronski RJ, Peehl DM, Feldman D,. Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-1960.
2. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF,. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998; 7: 391-395.
3. Skinner HG, Schwartz GG,. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 2302-2305.
4. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M,. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108: 104-108.
5. Woo TC, Choo R, Jamieson M, Chander S, Vieth R,. Pilot study: Potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005; 51: 32-36.
6. Wu G, Fan RS, Li W, Ko TC, Brattain MG,. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997; 15: 1555-1563.
7. Peng L, Malloy PJ, Feldman D,. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004; 18: 1109-1119.
8. Rohan JN, Weigel NL,. 1α,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009; 150: 2046-2054.
9. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP,. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997; 19: 15-27.
10. Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, Ting HJ, Ma WL, Lee YF,. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3. Am J Pathol 2011; 178: 872-880.
11. Blutt SE, McDonnell TJ, Polek TC, Weigel NL,. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000; 141: 10-17.
12. Guzey M, Kitada S, Reed JC,. Apoptosis induction by 1alpha,25- dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002; 1: 667-677.
13. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D,. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65: 7917-7925.
14. Maguire O, Pollock C, Martin P, Owen A, Smyth T, Doherty D, Campbell MJ, McClean S, Thompson P,. Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. Mol Cell Endocrinol 2012; 364: 54-64.
15. Huggins C, Stevens RE, Hodges CV,. Studies on prostatic Cancer II, the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223.
16. Roach M III, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV,. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-591.
17. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008; 299: 289-295.
18. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108: 13728-13733.
19. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
20. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-6415.
21. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M,. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004; 64: 765-771.
22. Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, Kitada M,. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998; 1380: 297-304.
23. Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH, Prough RA,. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab Dispos 2004; 32: 305-313.
24. Cheng Q, Sohl CD, Yoshimoto FK, Guengerich FP,. Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4. J Biol Chem 2012; 287: 29554-29567.
25. Jena S, Lee WP, Doherty D, Thompson PD,. PIAS4 represses vitamin D receptor-mediated signaling and acts as an E3-SUMO ligase towards vitamin D receptor. J Steroid Biochem Mol Biol 2012; 132: 24-31.
26. Miller GJ, Stapleton GE, Ferrara FA, Lucia MS, Pfister S, Hedlund TE, Upadhya P,. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992; 52: 515-520.
27. Schwartz GG, Oeler TA, Uskokovic̈ MR, Bahnson RR,. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994; 14: 1077-1081.
28. Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, Vuoristo JT, Edwards RJ, Paavonen TK,. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 2007; 28: 916-921.
29. Skowronski RJ, Peehl DM, Feldman D,. Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136: 20-26.
30. Shankar VN, Dilworth FJ, Makin HL, Schroeder NJ, Trafford DJ, Kissmeyer AM, Calverley MJ, Binderup E, Jones G,. Metabolism of the vitamin D analog EB1089 by cultured human cells: Redirection of hydroxylation site to distal carbons of the side-chain. Biochem Pharmacol 1997; 53: 783-793.
31. Kissmeyer AM, Binderup E, Binderup L, Mørk Hansen C, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G,. Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 1997; 53: 1087-1097.
32. Meyer MB, Goetsch PD, Pike JW,. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem 2010; 285: 15599-15610.
33. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP,. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263: 424-436.
34. Mäenpää J, Pelkonen O, Cresteil T, Rane A,. The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol 1993; 44: 61-67.
35. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U,. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001; 276: 38685-38689.
36. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U,. Metabolism of 4 beta -hydroxycholesterol in humans. J Biol Chem 2002; 277: 31534-31540.
37. Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, Katagiri M,. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 1998; 28: 539-547.
38. Leskelä S, Honrado E, Montero-Conde C, Landa I, Cascõn A, Letõn R, Talavera P, Cõzar JM, Concha A, Robledo M, Rodríguez-Antona C,. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer 2007; 14: 645-654.
39. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI,. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72: 6142-6152.
40. Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, Takayama K, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Homma Y, Inoue S,. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009; 74: 391-397.
41. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB,. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
42. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS,. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 901-905.
43. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM,. CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification ? Hum Genet 2002; 110: 553-560.
44. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL,. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003; 88: 928-932.
45. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E,. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
46. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS,. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 928-932.
47. Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J,. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer 2008; 122: 2511-2516.
48. Seo YK, Mirkheshti N, Song CS, Kim S, Dodds S, Ahn SC, Christy B, Mendez-Meza R, Ittmann MM, Abboud-Werner S, Chatterjee B,. SULT2B1b sulfotransferase: Induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol 2013; 27: 925-939.
49. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG,. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386-392.
50. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A,. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 2003; 54: 275-289.
51. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, Stolz A,. Impaired dihydrotestosterone catabolism in human prostate cancer: Critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 2007; 67: 1361-1369.
52. Soronen P, Laiti M, Törn S, Härkönen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala A, Kaija H, Isomaa V, Vihko P,. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281-286.
53. Kaeding J, Bélanger J, Caron P, Verreault M, Bélanger A, Barbier O,. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells. Mol Cancer Ther 2008; 7: 380-390.
54. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 243-258.